Boehringer Ingelheim - Top 13 Advertising Budgets

Company: Boehringer Ingelheim boehringer.jpg
2007 Ad Spending: $505.3 million
2006 Ad Spending: $191.8 million

Breakdown

  • Magazines: $63.4M
  • Newspaper: $900,000
  • Outdoor: $100,000
  • TV: $228.8M
  • Radio: $2.2M
  • Internet: $7.8M

Where Boehringer is spending money: As one of the few drugmakers to boost U.S. ad spending in 2007, Boehringer Ingelheim pumped up its budgets for several products. Its prostate drug Flomax got a 65 percent boost in spending to $87.3 million, and heartburn treatment Zantac saw a 29.9 percent hike to $41.9 million. But the biggest leaps came in spending on chronic obstructive pulmonary disease drug Spiriva and restless legs-slash-Parkinson's treatment Mirapex. Spending on Spiriva grew to $81 million from $22.9 million, and Mirapex got $60.9 million for its first big campaign.

Those big investments paid off: Spiriva "led the way" in boosting Boehringer's revenues, the company said in announcing its 2007 results. The COPD drug delivered a 35 percent boost in global sales to €1.8 billion. Mirapex sales grew 26 percent to 644 million euros. And Flomax posted a 19 percent rise to €1.02 billion.

Where Boehringer isn't spending money: Boehringer didn't push one of its biggest drugs via U.S. measured media: Micardis, a blood-pressure drug. The product nevertheless grew sales by 23 percent to $1.12 billion.

Boehringer Ingelheim - Top 13 Advertising Budgets
Read more on

Suggested Articles

The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here: Its crucial Humira follow-up, Rinvoq.

Bristol-Myers Squibb’s takeover of Celgene hasn’t always gone smoothly, but now a once-left-for-dead centerpiece of that deal is ready to launch.

Investors sued Novo Nordisk in Denmark, claiming it misled the public about trouble plaguing its insulin franchise—and demanding $1.75B in damages.